State Street Corp Buys 1,350,766 Shares of Abbott Laboratories $ABT

State Street Corp raised its position in Abbott Laboratories (NYSE:ABT) by 1.7% during the second quarter, Holdings Channel reports. The firm owned 80,926,234 shares of the healthcare product maker’s stock after purchasing an additional 1,350,766 shares during the period. State Street Corp’s holdings in Abbott Laboratories were worth $7,343,246,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Copley Financial Group Inc. raised its position in shares of Abbott Laboratories by 2.1% in the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after acquiring an additional 93 shares in the last quarter. WealthTrust Axiom LLC boosted its stake in Abbott Laboratories by 3.2% during the 4th quarter. WealthTrust Axiom LLC now owns 3,064 shares of the healthcare product maker’s stock valued at $384,000 after purchasing an additional 94 shares during the last quarter. Calton & Associates Inc. raised its stake in shares of Abbott Laboratories by 4.4% in the fourth quarter. Calton & Associates Inc. now owns 2,323 shares of the healthcare product maker’s stock worth $291,000 after purchasing an additional 97 shares during the last quarter. Private Wealth Asset Management LLC lifted its holdings in shares of Abbott Laboratories by 0.8% in the fourth quarter. Private Wealth Asset Management LLC now owns 13,055 shares of the healthcare product maker’s stock valued at $1,636,000 after purchasing an additional 100 shares in the last quarter. Finally, Arcadia Investment Management Corp MI lifted its stake in Abbott Laboratories by 3.1% during the 4th quarter. Arcadia Investment Management Corp MI now owns 3,359 shares of the healthcare product maker’s stock valued at $421,000 after acquiring an additional 101 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Up 1.0%

Shares of NYSE:ABT traded up $1.03 during trading on Tuesday, hitting $104.01. The stock had a trading volume of 2,637,689 shares, compared to its average volume of 11,461,565. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $179.98 billion, a PE ratio of 33.67, a PEG ratio of 1.90 and a beta of 0.59. The firm’s fifty day moving average is $106.57 and its 200 day moving average is $99.22. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $136.88.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The business’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is presently 81.55%.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ABT. UBS Group lowered their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Weiss Ratings raised shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday. Bank of America dropped their price target on Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $118.00 price objective (up from $115.00) on shares of Abbott Laboratories in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $119.50.

Abbott Laboratories Profile

Abbott Laboratories (NYSE: ABT) is a global healthcare company that develops, manufactures and sells medical products and technologies. Its operations span four principal areas: medical devices, diagnostics, established pharmaceutical products and nutrition. Abbott serves healthcare providers, institutions and consumers in markets around the world.

The company’s medical device portfolio includes products for cardiovascular care, diabetes management and other specialties. Its diagnostics business provides laboratory systems, tests and point-of-care solutions, while its nutrition products include infant, child and adult nutritional offerings sold under brands such as Similac, Ensure and Pedialyte.